We are live on ! Find out more
NFGH

Nan Fung Group Holdings Portfolio holdings

AUM $121M
1-Year Est. Return 56.89%
This Fund
S&P 500
This Quarter Est. Return
+13.46%
1 Year Est. Return
+56.89%
3 Year Est. Return
+244.35%
5 Year Est. Return
+210.19%
10 Year Est. Return
–
AUM
$156M
AUM Growth
+$9.51M
Cap. Flow
-$1.26M
Cap. Flow %
-0.81%
Top 10 Hldgs %
79.2%
Holding
49
New
5
Increased
3
Reduced
6
Closed
6

Top Buys

Rank Stock Value
1
KALV
KalVista Pharmaceuticals
KALV
+$1.16M
2
GERN icon
Geron
GERN
+$1.1M
3
KYNB
Kyntra Bio
KYNB
+$463K
4
CABA icon
Cabaletta Bio
CABA
+$446K
5
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$312K

Top Sells

Rank Stock Value
1
MELI icon
Mercado Libre
MELI
+$1.19M
2
GTLB icon
GitLab
GTLB
+$1.12M
3
BMEA icon
Biomea Fusion
BMEA
+$626K
4
TVTX icon
Travere Therapeutics
TVTX
+$576K
5
ASND icon
Ascendis Pharma A/S
ASND
+$447K

Sector Composition

Rank Sector Weight
1 Healthcare 99.77%
2 Technology 0.23%
3 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRTX
1
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$48.9M 31.28%
225,688
– –
ILMN icon
2
Illumina
ILMN
$29.5B
$22.3M 14.28%
122,533
– –
HRMY icon
3
Harmony Biosciences
HRMY
$2.08B
$13M 8.29%
368,665
– –
SGEN
4
DELISTED
Seagen Inc. Common Stock
SGEN
$9.06M 5.79%
47,096
– –
OCS icon
5
Oculis Holding
OCS
$655M
$8.03M 5.13%
651,100
– –
EXAI
6
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$5.09M 3.25%
859,892
– –
ISEE
7
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$4.41M 2.82%
111,984
– –
XENE icon
8
Xenon Pharmaceuticals
XENE
$6.1B
$4.4M 2.81%
114,380
– –
KDNY
9
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$4.38M 2.8%
113,950
– –
REPL icon
10
Replimune Group
REPL
$454M
$4.29M 2.74%
184,739
-4,600
-2% -$89.9K
MRUS
11
DELISTED
Merus
MRUS
$3.98M 2.54%
151,000
– –
SLGC
12
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$3.92M 2.5%
1,696,558
– –
ONC
13
BeOne Medicines Ltd
ONC
$33.9B
$2.14M 1.37%
12,022
– –
RANI icon
14
Rani Therapeutics
RANI
$94.8M
$2.03M 1.3%
493,584
– –
INCY icon
15
Incyte
INCY
$25.4B
$1.99M 1.27%
32,022
-2,369
-7% -$158K
GRTX
16
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$1.91M 1.22%
613,223
– –
KALV
17
DELISTED
KalVista Pharmaceuticals
KALV
$1.84M 1.18%
204,720
+126,000
+160% +$1.16M
PACB icon
18
Pacific Biosciences
PACB
$435M
$1.82M 1.16%
136,655
– –
BOLT icon
19
Bolt Biotherapeutics
BOLT
$7.4M
$1.49M 0.95%
58,348
– –
GERN icon
20
Geron
GERN
$898M
$1.25M 0.8%
+388,000
New +$1.1M
EXEL icon
21
Exelixis
EXEL
$13.9B
$1.23M 0.78%
64,200
– –
BMEA icon
22
Biomea Fusion
BMEA
$88.2M
$878K 0.56%
40,000
-20,000
-33% -$626K
JBIO
23
Jade Biosciences
JBIO
$1.18B
$822K 0.53%
1,370
– –
TRDA icon
24
Entrada Therapeutics
TRDA
$254M
$743K 0.47%
49,082
-24,500
-33% -$338K
EAR
25
DELISTED
Eargo, Inc. Common Stock
EAR
$729K 0.47%
147,904
– –
1
2

Similar funds

TCM
TT Capital Management Coto De Caza, California $121M AUM 1.94% 1-Year Est. Return
MAM
Mirabaud Asset Management London, United Kingdom $121M AUM 20.69% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
CCM
Candelo Capital Management New York $121M AUM 113.39% 1-Year Est. Return
CCM
CFO Capital Management Fairfield, Connecticut $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Nan Fung Group Holdings's Q2 2023 Portfolio in Review

As of Q2 2023, Nan Fung Group Holdings held 49 positions worth $156M, up 6.5% from $147M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Nan Fung Group Holdings's Q2 2023 filing shows 5 new, 3 increased, 6 reduced and 6 closed positions. Its largest new stake was Geron: 388,000 shares worth $1.25M. The largest sale was Mercado Libre, an estimated $1.19M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Nan Fung Group Holdings's largest Q2 2023 buy was Geron: 388,000 shares worth $1.25M.
  • Nan Fung Group Holdings added most to KalVista Pharmaceuticals in Q2 2023, an estimated $1.16M increase.
  • Nan Fung Group Holdings's biggest Q2 2023 reduction was GitLab, cutting an estimated $1.12M.
  • Nan Fung Group Holdings fully exited Mercado Libre in Q2 2023, selling an estimated $1.19M.
  • Nan Fung Group Holdings's ten largest holdings make up 79% of its $156M portfolio in Q2 2023.
  • Nan Fung Group Holdings opened 5 new positions and closed 6 in Q2 2023.
  • Nan Fung Group Holdings's portfolio value rose 6.5% quarter-over-quarter to $156M.

Based on Nan Fung Group Holdings's 13F filing for Q2 2023, filed 11 Aug 2023.